July 4th, 2022, Hamburg (GERMANY). This merger will strengthen their portfolio and help bring EvidentIQ’s offer to yet another level of expertise.
Today, EvidentIQ, a leading provider of end-to-end eClinical and Patient Insights solutions, announced the acquisition of DACIMA Software, a Canadian clinical software company founded in 2006.
EvidentIQ, based in Hamburg, is a leading clinical data science group, offering an end-to-end platform of state-of-the art eClinical solutions (eConsent, EDC, CTMS, eCOA,) that helps its customers with the planning and execution of both hybrid/decentralized and traditional clinical trials. Thanks to its global patient platform Carenity, the group combines their technology with a direct access to real-world patient insights, enabling them to support sponsors and CROs with innovative offerings such as eFeasibility, eRecruitment and Real-World Evidence data collection and analysis.
Dacima, based in Montreal, offers a cutting edge flexible Electronic Data Capture (EDC) platform for the design and management of clinical trials, observational studies, patient registries, clinical databases, electronic Patient Reported Outcomes (ePRO), eDiaries and eConsent. It’s advanced eClinical capabilities will enrich EvidentIQ Group product lineup with software solutions for electronic Clinical Outcome Assessment (eCOA) and eConsent. The company has been founded by experts in epidemiology, medical research and information technology who understand the needs of users and requirements of eClinical software for the healthcare sector.
By integrating EvidentIQ’s patient community, data science solutions and eClinical backbone with Dacima’s products, the group will provide the technology for hybrid and decentralized clinical trials (DCT) as a one-stop-shop on a global basis. This acquisition will help EvidentIQ to build a complete offer that covers every step in the value chain of clinical research and development, enhance their unique end-to-end solutions to help the life sciences industry run innovative patient-centric clinical studies and optimize clinical research.
Contact us for more information.